<?xml version="1.0" encoding="UTF-8"?>
<ref id="bib14">
 <label>14</label>
 <element-citation publication-type="journal" id="sref14">
  <person-group person-group-type="author">
   <name>
    <surname>Giugliani</surname>
    <given-names>R.</given-names>
   </name>
   <name>
    <surname>Giugliani</surname>
    <given-names>L.</given-names>
   </name>
   <name>
    <surname>de Oliveira Poswar</surname>
    <given-names>F.</given-names>
   </name>
   <name>
    <surname>Donis</surname>
    <given-names>K.C.</given-names>
   </name>
   <name>
    <surname>Corte</surname>
    <given-names>A.D.</given-names>
   </name>
   <name>
    <surname>Schmidt</surname>
    <given-names>M.</given-names>
   </name>
   <name>
    <surname>Boado</surname>
    <given-names>R.J.</given-names>
   </name>
   <name>
    <surname>Nestrasil</surname>
    <given-names>I.</given-names>
   </name>
   <name>
    <surname>Nguyen</surname>
    <given-names>C.</given-names>
   </name>
   <name>
    <surname>Chen</surname>
    <given-names>S.</given-names>
   </name>
   <name>
    <surname>Pardridge</surname>
    <given-names>W.M.</given-names>
   </name>
  </person-group>
  <article-title>Neurocognitive and somatic stabilization in pediatric patients with severe Mucopolysaccharidosis Type I after 52Â weeks of intravenous brain-penetrating insulin receptor antibody-iduronidase fusion protein (valanafusp alpha): an open label phase 1-2 trial</article-title>
  <source>Orphanet J. Rare Dis.</source>
  <volume>13</volume>
  <year>2018</year>
  <fpage>110</fpage>
  <pub-id pub-id-type="pmid">29976218</pub-id>
 </element-citation>
</ref>
